Learning Objectives
- Summarize the most impactful AML data presented at EHA 2026, including updates in frontline and relapsed/refractory settings.
- Discuss the most significant abstracts presented at the 2026 EHA in AML.
- Interpret new clinical trial results in AML through a Canadian clinical practice lens.
Moderators
Speakers
This program has been made possible through unrestricted support from Astellas.